BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020
- Hamoda, H.
- Davis, S.R.
- Cano, A.
- Morris, E.
- Davison, S.
- Panay, N.
- Lumsden, M.A.
- Hillard, T.
- Simoncini, T.
ISSN: 2053-3705, 2053-3691
Année de publication: 2021
Volumen: 27
Número: 1
Pages: 49-55
Type: Lettre
